Inmune Bio (INMB) Liabilities and Shareholders Equity (2017 - 2026)

Inmune Bio has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $25.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 31.7% year-over-year to $25.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.5 million (down 49.88% YoY) and the FY2025 annual result came in at $32.4 million, down 18.23% from the prior year.
• Liabilities and Shareholders Equity fell to $25.8 million in Q1 2026 per INMB's latest filing, from $32.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $94.4 million in Q1 2022 and troughed at $25.8 million in Q1 2026.
• A 5-year average of $58.3 million and a median of $54.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 44.66% in 2022, then tumbled 36.8% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $81.8 million in 2022, then plunged by 30.31% to $57.0 million in 2023, then sank by 30.59% to $39.6 million in 2024, then decreased by 18.23% to $32.4 million in 2025, then dropped by 20.19% to $25.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $25.8 million, $32.4 million, and $33.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.